647 related articles for article (PubMed ID: 22389253)
1. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
2. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
Nagehan P; Sabbir M; Song J; Mohammad H
J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
[TBL] [Abstract][Full Text] [Related]
3. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
4. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
5. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
[TBL] [Abstract][Full Text] [Related]
6. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract][Full Text] [Related]
7. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
8. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.
Komeno Y; Huang YJ; Qiu J; Lin L; Xu Y; Zhou Y; Chen L; Monterroza DD; Li H; DeKelver RC; Yan M; Fu XD; Zhang DE
Mol Cell Biol; 2015 Sep; 35(17):3071-82. PubMed ID: 26124281
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
10. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
[TBL] [Abstract][Full Text] [Related]
11. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; Ribate VE; Muñoz CM; Santillana SG; Taboada SE; Casterá ME; Abinzano CMJ; Barranco IA; Nieto CR; Pampliega VM; Blanco ML; de Andrés ÁS; de Oteyza PJ; Del Castillo BT; Font GI; Cayuela JA; Díez-Campelo M; Sánchez AR; Vercet SC; Díaz TM;
Cancer Med; 2023 Aug; 12(16):16788-16792. PubMed ID: 37403747
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Cook MR; Karp JE; Lai C
EJHaem; 2022 Feb; 3(1):301-313. PubMed ID: 35846202
[TBL] [Abstract][Full Text] [Related]
13. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.
Chen L; Chen JY; Huang YJ; Gu Y; Qiu J; Qian H; Shao C; Zhang X; Hu J; Li H; He S; Zhou Y; Abdel-Wahab O; Zhang DE; Fu XD
Mol Cell; 2018 Feb; 69(3):412-425.e6. PubMed ID: 29395063
[TBL] [Abstract][Full Text] [Related]
14. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.
Tatarian J; Tupper N; Li P; Feusier J; Abdo M; Hyter S; Gonzales PR; Zhang D; Woodroof J; Kelting S; Godwin AK; Cui W
Am J Clin Pathol; 2023 Nov; 160(5):490-499. PubMed ID: 37458189
[TBL] [Abstract][Full Text] [Related]
15. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.
Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
[TBL] [Abstract][Full Text] [Related]
17. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Tinsley-Vance SM; Ali NA; Ball S; Aguirre LE; Jain AG; Hussaini MO; Chan O; Kuykendall A; Sweet K; Lancet J; Padron E; Sallman DA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):355-359. PubMed ID: 36813626
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J; Urrutia S; Loghavi S; Short NJ; Issa GC; Maiti A; Abbas HA; Daver NG; Pemmaraju N; Pierce S; Chien KS; Sasaki K; Kadia TM; Hammond DE; Borthakur G; Patel K; Ravandi F; Kantarjian HM; Garcia-Manero G; DiNardo CD
Blood; 2023 Nov; 142(19):1647-1657. PubMed ID: 37441846
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.
Skrdlant L; Stark JM; Lin RJ
BMC Mol Biol; 2016 Aug; 17(1):18. PubMed ID: 27552991
[TBL] [Abstract][Full Text] [Related]
20. Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.
Adamska M; Kowal-Wiśniewska E; Czerwińska-Rybak J; Kiwerska K; Barańska M; Gronowska W; Loba J; Brzeźniakiewicz-Janus K; Wasilewska E; Łanocha A; Jarmuż-Szymczak M; Gil L
Contemp Oncol (Pozn); 2023; 27(4):269-279. PubMed ID: 38405213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
